Benitec Biopharma Inc. (BNTC) financial statements (2022 and earlier)

Company profile

Business Address 3940 TRUST WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,32919,7699,801
Cash and cash equivalents12,32919,7699,801
Receivables  59
Other current assets  949
Other undisclosed current assets343839 
Total current assets:12,67220,60810,809
Noncurrent Assets
Operating lease, right-of-use asset888202395
Property, plant and equipment268375374
Other noncurrent assets161185 
Other undisclosed noncurrent assets2599
Total noncurrent assets:1,342771778
TOTAL ASSETS:14,01421,37911,587
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,281737890
Accounts payable682274282
Accrued liabilities278187405
Employee-related liabilities321276203
Other undisclosed current liabilities1,199632246
Total current liabilities:2,4801,3691,136
Noncurrent Liabilities
Long-term debt and lease obligation698 213
Operating lease, liability698 213
Other undisclosed noncurrent liabilities(698) (213)
Total noncurrent liabilities:698 213
Total liabilities:3,1781,3691,349
Stockholders' equity
Stockholders' equity attributable to parent10,83620,01010,238
Common stock111
Additional paid in capital152,093151,583128,826
Accumulated other comprehensive loss(1,273)(1,455)(1,953)
Accumulated deficit(139,985)(130,119)(116,636)
Total stockholders' equity:10,83620,01010,238
TOTAL LIABILITIES AND EQUITY:14,01421,37911,587

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
Revenues2859102
Gross profit:2859102
Operating expenses(17,333)(13,655)(8,383)
Operating loss:(17,305)(13,596)(8,281)
Nonoperating income (expense)(473)(286)7
Foreign currency transaction loss, before tax(470)(333)(88)
Other nonoperating income 3734
Net loss available to common stockholders, diluted:(17,778)(13,882)(8,274)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
Net loss:(17,778)(13,882)(8,274)
Comprehensive loss:(17,778)(13,882)(8,274)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent294498(89)
Comprehensive loss, net of tax, attributable to parent:(17,484)(13,384)(8,363)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: